Changes in Hong Kong stocks | Hengrui Pharmaceutical (01276) rose more than 4%, two innovative drugs for prostate cancer were approved for clinical use, and no similar products were approved for listing at home or abroad

Zhitongcaijing · 6d ago

The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose by more than 4%. As of press release, it had risen 4.36% to HK$77.8, with a turnover of HK$103 million.

According to the news, recently, Hengrui Pharmaceutical announced that its two innovative drugs, HRS-4357 injection and HRS-5041 tablets, have been approved by the State Drug Administration to jointly conduct clinical trials to treat prostate-specific membrane antigen (PSMA) -positive prostate cancer.

HRS-4357 is a chemical class 1 radiotherapy drug. This approval is a new expansion based on its single-agent clinical trial. HRS-5041 is a novel androgen receptor proteolytic target chimera (AR PROTAC) small molecule drug designed to treat prostate cancer by degrading AR protein, and has the potential to overcome resistance to existing therapies. According to the announcement, no similar products have been approved for listing at home or abroad.